ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

Olivier Rixe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.